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cal data for lung metastasis, primary and secondary liver cancer, locally advanced 
pancreatic cancer population treated with CyberKnife radiation. Searching using 
Medline, EMBASE, Cochrane Library took place in September 2013. Results: Only 
one relevant comparative clinical study (matched-pair analysis) met the inclusion 
criteria, assessing effectiveness and safety of stereotactic radiosurgery and radi-
ofrequency ablation for colorectal liver metastasis. For other neoplasms single-arm 
studies were found. Compared to RFA CyberKnife for liver metastasis was signifi-
cantly better in median local disease free survival, which was 34.4 months vs. 6.0 
months, (p< 0.001). 1 and 2-year local control rates also favored CK (85.0% vs. 65.0% 
and 80.0% vs. 61.0%, respectively) but the difference wasn’t significant. However, 
trend for better OS was found with RFA (34.4 vs. 52.3 months). For lung metastasis, 
treatment with CK resulted in 24.0-62.0% complete or partial response, 38.0-76.0% 
patients stabilized. In primary liver tumors OR (CR + PR) was observed in 63.0-86.0% 
patients, 0.0-29.0% stabilized, median PFS reached 10.0-15.8 months. Inconsistent 
results were seen in locally advanced pancreatic cancer population. In one study 
92.0% responded or stabilized but in other only 1 patient of 77 had PR. Median OS 
was 6.4-10.3 months. All studies reported mostly mild adverse events after CK. 
Serious AE were rare. ConClusions: There is limited quality evidence on the 
effectiveness and safety of robotic image-guided stereotactic radiosurgery in 
patients with soft tissue neoplasms. Available studies are highly heterogenic in 
methods, patients characteristics and outcomes but suggest that CyberKnife may 
be beneficial in local tumor control. There is a need of well-designed comparative 
studies.
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objeCtives: For patients with relapsed or refractory (R/R) chronic lymphocytic 
leukemia (CLL), treatment outcomes are poor and treatment options are limited. 
Ibrutinib is an oral, once-a-day, first-in-class covalent inhibitor of Bruton’s tyrosine 
kinase approved by the Food and Drug Administration (FDA) for R/R CLL. In a recent 
phase III trial (PCYC-1112), ibrutinib was associated with improved progression-free 
survival (PFS, hazard ratio [HR] = 0.215) and overall survival (OS, HR= 0.387) versus 
ofatumumab. The aim of this study is to provide a summary and analysis of results 
observed with current therapies in high-risk patients with R/R CLL. Methods: 
A systematic literature review and targeted literature search of clinical trials and 
international treatment guidelines in PubMed/MEDLINE (January 1,2001–April 
28,2013) and ASCO/ASH/EHA conference proceedings (2011–2013) were conducted 
to identify and evaluate current treatment options for R/R CLL, including alem-
tuzumab, rituximab, bendamustine, chlorambucil, and ofatumumab. Results: 
Study results highlight poor outcomes with existing treatment options and 
continuously high unmet need in patients. Sixteen trials were identified; the 
majorities were single-arm with small sample sizes, making comparative effec-
tiveness difficult to establish. Time-to-treatment failure was 5.8 months with 
alemtuzumab, while median PFS was 5.5 months with rituximab, 5.5–5.7 months 
with ofatumumab, 8 months with chlorambucil-ritiximab, and 15.2 months in 
previously-treated patients and 6.8 months in previously-treated patients with 
del (17p) with bendamustine-rituximab. Ofatumumab has demonstrated activ-
ity in patients with difficult-to-treat, high-risk CLL and is the only recognized 
and approved treatment by health authorities globally in this treatment setting 
and recommended in treatment guidelines. ConClusions: The lack of standard 
of care creates challenges for defining comparators in clinical trials and health 
technology assessments. In R/R CLL with high-risk features, ofatumumab is an 
appropriate comparator. Interim results from the phase III RESONATE trial showed 
that ibrutinib achieved significantly improved efficacy versus ofatumumab, even 
in high-risk disease patients.
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objeCtives: MTC is a rare form of thyroid cancer with prevalence of less than 7 per 
100,000. A majority of MTC patients have RET mutations, and RET M918T mutations 
are associated with especially poor prognosis. In 2012, EMA approved the first tyros-
ine kinase inhibitor (TKI) CAPRELSA® (vandetanib, VDB) for the treatment of MTC. 
In March 2014, the EMA approved another TKI -COMETRIQ® (cabozantinib, CBZ) for 
the treatment of adult patients with progressive, unresectable locally advanced or 
metastatic MTC, with orphan drug status. The objective of this study was to assess the 
relative efficacy in PFS and OS of CBZ vs VDB. Methods: Since there are no clinical 
trials directly comparing the two treatments, an adjusted indirect comparison (Bucher 
et al. method) was used. Evidence on PFS for the two treatments was collected from 
the pivotal clinical trials in MTC. The analysis considered all patients and a subgroup 
of RET M918T mutation positive (RET+) patients. Our analysis focused on PFS due 
to lack of evidence for the VDB OS in the RET M918T mutation subgroup. In the all 
patients analysis three different scenarios were explored: a logrank model to ensure 
comparability with the VDB data; a Cox model stratified on age at randomization and 
prior TKI status; and a Cox model without stratifications. Results: In the subgroup 
analysis (logrank model) PFS was estimated to increase by 65% with CBZ comparing 
to VDB (HR 0.35; 95% CI 0.14-0.87). In the all-patients analysis the estimates were less 
conclusive: logrank model (HR 0.72; 0.40-1.28), Cox model with stratifications (HR 0.61; 
0.35-1.04), Cox model without stratifications (HR 0.66; 0.39-1.13). ConClusions: The 
results showed a positive trend in favour of CBZ in PFS. Given the limited evidence a 
direct head-to-head comparison is necessary to validate the study findings.
K-M graphs. ConClusions: Due to very limited availability of trials with robust 
endpoints and long-term follow-up, alternative options for establishing compara-
tive efficacy must be used for decision making in relapsed or refractory MCL. These 
alternatives include implementing comparisons of single-arm trial data without 
adjustment (i.e., via naïve comparison) or methods such as match-adjusted indi-
rect comparison (MAIC) to derive comparative estimates. MAIC is a relatively novel 
method and may be difficult to implement given the heterogeneity in trial designs 
and patient-level characteristics in MCL trials. The scarcity of K-M data to inform 
PFS and OS of certain comparators further limits the comparisons that can be made 
through modeling.
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objeCtives: The prognosis of patients with metastatic cervical cancer (CC) remains 
poor, and treatment options are limited, with no single agent or combination of 
agents recognised as standard of care; cisplatin/paclitaxel is the therapy most cited 
by guidelines. This study aimed to assess the efficacy of reported treatment options 
for patients with metastatic CC. Methods: Searches of PubMed were conducted, 
with no date restrictions, to identify published randomised controlled Phase II/III 
clinical trials (RCTs) of chemotherapies recommended by treatment guidelines, 
and radiotherapy and/or surgery, that reported overall survival (OS) in patients with 
metastatic (systemic recurrent, persistent or de novo-metastatic) CC. Treatment 
guidelines and the Cochrane Library were also explored to identify additional cita-
tions. Results: Of 65 articles identified, 10 articles published between 1987 and 
2014 proceeded to data extraction. Evidence supporting the use of chemotherapy 
was limited to cisplatin-monotherapy or platinum-based combination therapy. 
Overall the OS benefit of these agents ranged from 0.9 to 2.9 months and 0.79 to 
1.32 for hazard ratio (HR). The latest innovation, bevacizumab plus chemotherapy, 
demonstrated the greatest significant gain in OS versus chemotherapy (OS gain 
3.7 months; HR 0.71; p= 0.004). The study did not identify any RCTs that supported 
the use of surgery and/or radiotherapy in this setting; the evidence was limited to 
seven retrospective hospital based studies. ConClusions: This study highlighted 
an unmet need for additional treatment options for metastatic CC. Use of cispl-
atin-monotherapy or platinum-based combination therapy has provided limited 
survival benefits for many decades. The novel combination of bevacizumab plus 
chemotherapy has demonstrated an increase in survival in these patients. However, 
since there is no RCT evidence supporting the use of surgery and/or radiotherapy, 
a health technology appraisal of these alternative interventions is not currently 
feasible. Additional clinical research is urgently needed to assess the comparative 
clinical value of these therapies.
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objeCtives: Abiraterone acetate plus predniso(lo)ne (AA) and enzalutamide (E) 
are novel therapies for the treatment of metastatic castration-resistant prostate 
cancer in chemotherapy naïve patients. Pivotal trials have been conducted evalu-
ating the efficacy of the drugs using different comparators. In the COU-AA-302 
trial, patients were randomised between AA and active comparator predniso(lo)
ne whereas in the PREVAIL trial, E was compared against placebo. For health 
economic purposes, the mean overall survival (OS) and radiographic progression-
free survival (rPFS) of both novel agents need to be compared in the absence 
of head-to-head trial data. Methods: Due to the difference in the comparator 
arms, only survival data from AA and E were used for the comparison. Observed 
individual level survival data with baseline patient characteristics were available 
for AA. Individual survival data were simulated for E to replicate the rPFS and OS 
curves published for the pivotal trial. rPFS and OS were modeled and extrapolated 
by fitting parametric survival functions. The Weibull, exponential, and lognor-
mal models were evaluated based on statistical and clinical considerations, i.e. 
assessing the model fit and the implied hazard profiles, respectively. To control 
for differences in baseline patient characteristics (PSA, ECOG, Gleason score, BPI, 
LDH, metastasis, age, race) rPFS and OS estimates for AA were adjusted using a 
matching algorithm. Results: The Weibull models were selected for extrapo-
lation of both OS and rPFS. The mean rPFS was estimated to be 23.9 (95% CI: 
21.5-26.3) and 19.5 (95% CI: 16.0-23.9) months for AA and E respectively. Mean OS 
was estimated to be 38.7 (95% CI: 36.4-40.7) and 34.6 (95% CI: 31.8-37.8) months 
respectively. ConClusions: Based on currently available data and the presented 
modeling approach, these findings suggest that AA is associated with longer mean 
rPFS and OS than E.
PCN13
CliNiCAl effeCTiVeNess of roboTiC imAge-guided sTereoTACTiC 
rAdiosurgery (CyberkNife) iN seleCTed PrimAry ANd seCoNdAry sofT 
Tissue NeoPlAsms: A sysTemATiC reView
Wlodarczyk A., Ceglowska U., Slomka M., Luchowska K.
Agency for Health Technology Assessment In Poland (AHTAPol), Warsaw, Poland
objeCtives: Effectiveness of radiosurgery for head and spinal neoplasms is 
established. The aim of this study was to systematically review the clinical lit-
erature of CyberKnife for people with selected primary and secondary soft tissue 
lesions. Methods: A systematic search was conducted for best available clini-
